Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VHB937 · 2 trials · 2 indications
The CDR is a measure of cognition and function, widely used in clinical research in AD. The scale assesses six domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care. Based on in-depth semi-structured interview, each domain is assigned a score, which is summed to obtain the Sum of Boxes (SB) score, ranging from 0 to 18 with higher scores indicating worse condition
To compare the efficacy of VHB937 vs. placebo on a composite of permanent assisted ventilation (PAV) free survival and function in DB epoch
| Arm | Type | Description |
|---|---|---|
| VHB937 Low Dose | EXPERIMENTAL | I.V. infusions |
| VHB937 High Dose | EXPERIMENTAL | I.V. infusions |
| Placebo | PLACEBO_COMPARATOR | I.V. infusions |
| Arm 1 | EXPERIMENTAL | I.V. infusions |
| Arm 2 | PLACEBO_COMPARATOR | I.V. infusions |
| Name | Type | Description |
|---|---|---|
| VHB937 | BIOLOGICAL | VHB937 solution for infusion |
| Placebo | OTHER | Solution for infusion |
Key Inclusion Criteria * Male or female participants 50 to 85 years of age * Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD * Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0 * Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging * Re...
Top 20 of 30 competitors
VHB937 is an investigational monoclonal antibody developed by Novartis AG for neurological diseases. It is being studied in Phase 2 clinical trials in early Alzheimer's disease and in amyotrophic lateral sclerosis (ALS). VHB937 has not been approved for any use and remains in clinical development.
VHB937 is being evaluated as a treatment for early Alzheimer's disease and for amyotrophic lateral sclerosis (ALS). Both are neurological conditions, and the Phase 2 trials are designed to assess the effects of VHB937 in people with these diseases. No approved use has been established.
VHB937 is developed by Novartis AG, which trades under the ticker NVS. Novartis is sponsoring the Phase 2 clinical program evaluating VHB937 in early Alzheimer's disease and in amyotrophic lateral sclerosis (ALS).
VHB937 is in Phase 2 clinical development. Two Phase 2 trials are ongoing, one in early Alzheimer's disease and one in amyotrophic lateral sclerosis (ALS). Both studies are active but no longer recruiting participants. VHB937 is investigational and has not been approved by the FDA.
VHB937 is being studied in two Phase 2 trials. NCT07094516 evaluates VHB937 in people with early Alzheimer's disease and enrolled 97 participants across the United States, Europe, Asia and Australia. NCT06643481 evaluates VHB937 in amyotrophic lateral sclerosis (ALS) and enrolled 251 participants across a similar international set of countries. Both are randomized, double-blind and placebo-controlled.